Pharmaceutical Continuous Manufacturing Market Scope And Analysis

Report Code : TIPRE00008245
Category : Life Sciences

No. of Pages : 150

Buy Now

Pharmaceutical Continuous Manufacturing Market Scope and Key Players Analysis by 2031

Buy Now

Pharmaceutical Continuous Manufacturing Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 2.08 Billion
Market Size by 2031	US$ 4.67 Billion
Global CAGR (2023 - 2031)	10.6%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Product Integrated Systems Semi-Continuous Systems Controls By Application End Product Manufacturing API Manufacturing By End User Full-Scale Manufacturing Companies R&D Departments
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	GEA Group Coperion GmbH Gericke AG Glatt GmbH Hosokawa Micron Group Munson Machinery Co Inc Powrex Corp Thermo Fisher Scientific Inc Freund vector Corporation Fette Compacting

Pharmaceutical Continuous Manufacturing Market News and Recent Developments

The Pharmaceutical Continuous Manufacturing market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the Pharmaceutical Continuous Manufacturing market are listed below:

South Korea-based contract development and manufacturing organization (CDMO) SK Bioscience has broken ground on an approximately 4,200 m2 expansion of its L House vaccine manufacturing facility in Andong, Gyeongsangbuk-do, South Korea, which will serve as the production base for pneumococcal conjugate vaccine candidate GBP410, jointly developed by SK Bioscience and Sanofi, who are co-investing in the expansion. (SK Bioscience, Press Release, March 2024)
Phlow Corp., a US-based essential medicines public benefit company, announced strategic alliances with both Virginia Commonwealth University’s (VCU) Medicines for All Institute and AMPAC Fine Chemicals to provide contract continuous manufacturing research and development (R&D) services for small molecule pharmaceutical products. In addition to its robust and growing internal capabilities, Phlow’s network of established, innovative, and experienced strategic partners will provide high quality, US-based advanced manufacturing solutions for small molecule active pharmaceutical ingredients (APIs) and registered starting materials (RSMs) across all stages of development using state-of-the-art technologies and unique industry insights. (Phlow Corp., News, March 2022)

Pharmaceutical Continuous Manufacturing Market Report Coverage and Deliverables

The “Pharmaceutical Continuous Manufacturing Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

Pharmaceutical continuous manufacturing market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Pharmaceutical continuous manufacturing market trends as well as market dynamics such as drivers, restraints, and key opportunities
Detailed PEST and SWOT analysis
Pharmaceutical continuous manufacturing market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the pharmaceutical continuous manufacturing market
Detailed company profiles